The FDA has granted priority review to Ultragenyx's Biologics License Application (BLA) for UX111, a gene therapy for Sanfilippo syndrome type A (MPS IIIA).
A review of studies highlights several non-opioid medications with potential benefits for chronic low back pain (CLBP), myofascial pain syndrome (MPS), and fibromyalgia (FM).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.